- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
Biomarkers of Kidney Disease (NGAL et al..)
The Title says it all, Biomarkers of Kidney Disease by Charles Edelstein (and a string of noteworthy contributors) is a remarkable book collecting practically all the knowledge available on biomarkers.
For the avid reader of these pages – the book contains new groundbreaking new info – it does however give an excellent summary of the current knowledge and it a very thorough introduction to the fascinating world of biomarkers, and how they will transform the way we identify AKI (acute Kidney Injury) and development i CKD (Chronic Kidney Disease) and CIN (Contrast Induced Nepropathy)
on AKI; Clearly, NGAL represents a novel predictive biomarker for AKI and itsoutcomes
on CKD; There is anemerging literature suggesting that urine NGAL is also a marker of CKD and its severity.
on CIN; By multivariate analysis, the 2 h NGAL concentrations in the urine and plasma, but not patient demographics or contrast volume,were found to be powerful independent predictors of CIN.
As the closing remarks of the foreword says: Louis Pasteur stated, “Science knows no country, because knowledge belongs to humanity and is the torch which illuminates the world.”
Amongst the contributors we find the Grand old Man of NGAL-research Dr. Prasad Devarajan and also Dr. Michael Bennett, both of CCH (Cincinatti Childrens Hospital)
The book itself is highly recommended for those seeking up-to-date knowledge on the advantages of using biomarkers, the specifics and advantages/disadvantages …
NGAL – being the most promising biomarker of all – is discussed and analyzed first… – so if you just need a glimpse of the interesting world of biomarkers to make up your mind about investing in the ONLY company who has a homogenous NGAL-test applicable for all major RA’s – you just need to read chapter 1….
http://www.scribd.com/doc/97852607/0123756723
About Stengaard
BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂
Related posts:
- Is NGAL the Troponin of the kidney? An article in Clinical Laboratory Online, written by Dr. Marlies Ostermann and...
- NGAL, biomarker of acute kidney injury Another interesting article about NGAL as a marker for AKI,...
- Dr. Prasad Devarajan on NGAL Dr. Devarajan has made a more comprehensive explanation of the...
- More, more, more…Und wieder in Deutsch Every survey we see these days, seems to reach the...
- Battle of the biomarkers. (NGAL prevails) Geneva University Hospital has examined the 5 most promising markers....
Ongoing debate
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife